Skip to main content
. Author manuscript; available in PMC: 2010 Jun 1.
Published in final edited form as: Clin Pharmacol Ther. 2009 Mar 18;85(6):615–622. doi: 10.1038/clpt.2009.27

Figure 4.

Figure 4

Overall survival among patients receiving TBI 12 Gy plus standard CY dosing (120 mg/kg) vs. personalized CY dosing by type of hematologic malignancy (A and B) and by risk of relapse of malignancy after transplant (C and D).